A new patent application for IRLAB’s drug candidate IRL752 has been published by World Intellectual Property Organization, WIPO
IRLAB announced today that the World Intellectual Property Organization, WIPO, has published a new patent application for the drug candidate IRL752. The patent application regards a new substance patent, ‘composition of matter patent’ which, if granted in the forthcoming national application phases, may extend the market exclusivity of IRL752 by up to 10 years in relation to today’s patent protection. In connection with the publication of IRLAB’s patent application, WIPO also published an International Search Report (ISR) and a patentability statement, Written Opinion (WO).
Today, the drug candidate IRL752 is protected by an approved composition of matter patent in all important markets around the world. As part of IRLAB’s continuous intellectual property work, the company has applied for a patent to strengthen the strategic IP protection around IRL752. The patent application relates, inter alia, to a new salt of IRL752 that is intended to be included in the final pharmaceutical product. From the ISR and the patentability written opinion (WO), it appears as the new salt in the patent application meets the requirements for novelty, inventiveness and industrial applicability.
“We continuously work to improve our products and we apply for patents for our inventions. This work, when patents are granted, leads to strengthened protection around our research projects and drug candidates. If this new patent application for IRL752 is approved in the forthcoming national application phases, IRL752 may be protected by two strong patent families until the end of the 2030s or longer”, says Clas Sonesson, IRLAB’s Chief Scientific Officer.
For further information
Nicholas Waters, CEO
Phone: +46 730 75 77 01
Clas Sonesson, CSO
Phone: +46 730 75 77 00
IRLAB is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease.
IRLAB has two clinical candidate drugs, IRL752 and IRL790, focused on medical needs in Parkinson’s disease. IRLAB also has additional programs in pre-clinical stages.
IRLAB’s research is aimed at discovery and development of new candidate drugs addressing unmet medical need in diseases of the central nervous system, using the unique and proprietary integrative screening process, ISP.
IRLAB is based in Gothenburg, Sweden. The operations are mainly carried out through the subsidiary Integrative Research Laboratories Sweden AB.
For more information, please visit www.irlab.se.